等待开盘 09-26 09:30:00 美东时间
-0.720
-2.38%
BTIG analyst Ryan Zimmerman downgrades Vericel (NASDAQ:VCEL) from Buy to Neutral.
09-17 18:07
今日重点评级关注:花旗:维持Apellis Pharmaceuticals"买入"评级,目标价从46美元升至52美元;BTIG:维持Strategy"买入"评级,目标价从620美元升至700美元
08-04 09:30
Canaccord Genuity analyst Caitlin Cronin maintains Vericel (NASDAQ:VCEL) with a Buy and lowers the price target from $61 to $58.
08-02 04:58
Vericel shares are trading lower after the company reported a Q2 revenue miss.
07-31 20:45
2025 Financial GuidanceReaffirmed MACI full-year revenue growth in the low 20% rangeUpdated Burn Care revenue guidance for the second half of 2025 to be in line with recent run rate of approximately $10 million per
07-31 20:11
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
Major earnings expected before the bell on Thursday include: AbbVie (OTC:ABBY) Bristol-Myers Squibb Company (BMY) Mastercard Incorporated (MA) CVS Health Corporation (CVS) Shell plc (SHEL) Other earni...
07-31 06:00
<p>Vericel Corporation, a leader in advanced therapies for sports medicine and severe burn care, announced it will report its second-quarter 2025 financial results on July 31, 2025. Management will host a conference call and webcast at 8:30 a.m. ET to discuss financial results and business highlights. The live webcast can be accessed on Vericel's Investor Relations website, with presentation slides and a replay available. Investors can join by ph...
07-17 12:30
Vericel Corporation will participate in a fireside chat at the Truist Securities MedTech Conference on June 17, 2025. A webcast will be available on its Investor Relations website. The company specializes in advanced therapies for sports medicine and severe burn care, with products including MACI for knee cartilage repair, Epicel for burn treatment, and NexoBrid for eschar removal. More information is available at www.vcel.com.
06-10 12:30
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1132593314765758464.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通:维持IDEAYA Biosciences(IDYA)"超配"评级,目标价从63美元升至66美元</p> <p>• Needham:上调Inogen(INGN)评级至"买入",目标价12美元</p> <p>• E
05-23 11:19